NEW YORK – Genomics company SeqWell announced on Thursday that it has formed a strategic partnership and investment relationship with Codexis, a Redwood City, California-based enzyme engineering company, to accelerate the commercialization of its genomics workflow solutions.
In addition, Beverly, Massachusetts-based SeqWell said it raised $7 million in Series C financing, led by Codexis with a $5 million investment. The company's current investors, Research Corporation Technologies and BroadOak Capital Partners, also participated in this round.
Through the collaboration, SeqWell will pair its PlexWell next-generation sequencing library preparation technology with Codexis' CodeEvolver platform for discovering and developing novel, high-performance enzymes and biotherapeutics. The partnership is intended to advance SeqWell’s genomics workflow and library preparation products, the companies said.
"This investment amplifies Codexis' strategic growth ambitions in the life science tools area and accelerates SeqWell's ability to bring exciting new products to market by leveraging Codexis' enzyme engineering capabilities," said Rob Wilson, senior VP and general manager of Codexis' Performance Enzymes business unit, in a statement. Wilson will also join SeqWell’s board.